When is the next results date for Lincoln Pharma.?

No Upcoming Board Meetings

Who are in the management team of Lincoln Pharma.?

As of March 2022, the management team of Lincoln Pharma includes Chairman Kishorbhai M Shah, Managing Director Mahendra G Patel, and several Whole-time Directors, along with independent directors and a Company Secretary, reflecting a diverse leadership structure.

As of March 2022, the management team of Lincoln Pharma includes the following members:<BR><BR>1. Kishorbhai M Shah - Chairman (Non-Executive)<BR>2. Mahendra G Patel - Managing Director<BR>3. Hasmukhbhai I Patel - Whole-time Director<BR>4. Munjal Mahendrabhai Patel - Whole-time Director<BR>5. Aashish R Patel - Whole-time Director<BR>6. Anand Arvindbhai Patel - Whole-time Director<BR>7. Trusha Shah - Company Secretary & Compliance Officer<BR>8. Pirabhai R Suthar - Independent Director<BR>9. Meha Patel - Independent Director<BR>10. Saurin J Parikh - Independent Director<BR>11. Rajnikant G Patel - Director<BR><BR>This team comprises a mix of executive and independent directors, reflecting a diverse leadership structure within the company.

What does Lincoln Pharma. do?

Lincoln Pharmaceuticals Ltd manufactures and trades pharmaceutical products and is classified as a Small Cap company with a market cap of Rs 1,142 Cr. As of March 2025, it reported net sales of 168 Cr and a net profit of 12 Cr.

Overview: <BR>Lincoln Pharmaceuticals Ltd is engaged in the manufacturing and trading of pharmaceutical products within the Pharmaceuticals & Biotechnology industry, classified as a Small Cap company.<BR><BR>History: <BR>The company was incorporated in January 1979 as a Partnership Firm and was converted into a Public Limited Company in January 1995. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>- Net Sales: 168 Cr (Quarterly Results - Mar 2025) <BR>- Net Profit: 12 Cr (Quarterly Results - Mar 2025) <BR>- Market Cap: Rs 1,142 Cr (Small Cap) <BR><BR>Key Metrics: <BR>- P/E: 14.00 <BR>- Industry P/E: 35 <BR>- Dividend Yield: 0.00% <BR>- Debt Equity: -0.29 <BR>- Return on Equity: 12.26% <BR>- Price to Book: 1.70 <BR><BR>Contact Details: <BR>- Address: Lincoln House B/H Satyam Compe, Science City Road Sola Ahmedabad Gujarat : 380060 <BR>- Tel: 91-079-67778000 <BR>- Email: info@lincolnpharma.com <BR>- Website: http://www.lincolnpharma.com

Has Lincoln Pharma. declared dividend?

Yes, Lincoln Pharmaceuticals Ltd has declared a 15% dividend, amounting to 1.5 per share, with an ex-date of September 15, 2023. While recent total returns show volatility, longer-term performance over five years has been positive, with a total return of 247.97%.

Lincoln Pharmaceuticals Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 1.5<BR>- Ex-date: 15 Sep 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -37.95%, the dividend return was 0%, resulting in a total return of -37.95%.<BR><BR>Over the past year, the price return was -2.18%, the dividend return was 0%, leading to a total return of -2.18%.<BR><BR>In the 2-year period, the price return was 51.57%, the dividend return was 0.37%, culminating in a total return of 51.94%.<BR><BR>For the 3-year period, the price return was 98.05%, the dividend return was 1.06%, resulting in a total return of 99.11%.<BR><BR>In the last 4 years, the price return was 96.75%, the dividend return was 1.42%, leading to a total return of 98.17%.<BR><BR>Finally, over the past 5 years, the price return was 245.19%, the dividend return was 2.78%, resulting in a total return of 247.97%.<BR><BR>Overall, while Lincoln Pharmaceuticals has declared a dividend, the recent total returns indicate significant volatility, particularly in the short term, with negative returns over the last 6 months and 1 year. However, the longer-term returns show a more positive trend, especially over the 5-year period.

Who are the peers of the Lincoln Pharma.?

Lincoln Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Anuh Pharma, Wanbury, Kopran, Kwality Pharma, and Fermenta Biotec. Lincoln Pharma shows below-average growth and the lowest 1-year return among its peers at -3.74%.

Peers: The peers of Lincoln Pharma. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Anuh Pharma, Wanbury, Kopran, Kwality Pharma, and Fermenta Biotec.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Lincoln Pharma., Anuh Pharma, Wanbury, Kopran, and Kwality Pharma. Below Average management risk is noted at Fermenta Biotec. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen at Lincoln Pharma., Torrent Pharma, Kopran, and the rest. Average growth is noted for Anuh Pharma and Wanbury, with Kwality Pharma also showing Below Average growth. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Lincoln Pharma., Anuh Pharma, and Kwality Pharma, while Good is observed at Torrent Pharma and Kopran, and Below Average at Wanbury and Fermenta Biotec.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Wanbury at 104.73%, while the lowest is Lincoln Pharma. at -3.74%. Lincoln Pharma.'s return is significantly lower than the average of its peers. Additionally, the six-month return is negative for Lincoln Pharma., Torrent Pharma, and Fermenta Biotec.

Is Lincoln Pharma. overvalued or undervalued?

As of May 26, 2025, Lincoln Pharma is considered an attractive investment, assessed as undervalued with a PE Ratio of 13.92, an EV to EBITDA of 9.36, and a ROCE of 18.63%, significantly lower than peers like Sun Pharma and Divi's Lab, indicating strong growth potential despite recent stock performance declines.

As of 26 May 2025, the valuation grade for Lincoln Pharma has moved from very attractive to attractive. The company is currently assessed as undervalued. Key ratios include a PE Ratio of 13.92, an EV to EBITDA of 9.36, and a ROCE of 18.63%. <BR><BR>In comparison to its peers, Lincoln Pharma's PE Ratio is significantly lower than Sun Pharma's 35.25 and Divi's Lab's 79.33, indicating a more favorable valuation. Additionally, while Lincoln Pharma has a PEG Ratio of 0.00, suggesting strong growth potential relative to its price, competitors like Cipla and Dr. Reddy's Labs have PEG Ratios of 0.97 and 14.54, respectively. Despite a recent decline in stock performance year-to-date, Lincoln Pharma has outperformed the Sensex over a three-year period, reinforcing its potential as an undervalued investment in the pharmaceuticals sector.

Should I buy, sell or hold Lincoln Pharma.?

Who are the top shareholders of the Lincoln Pharma.?

The top shareholders of Lincoln Pharma include promoter Munjal Mahendrabhai Patel with 13.37%, individual investors at 36.27%, and 53 foreign institutional investors holding 5.14%. The highest public shareholder is Kishor M. Shah with 2.39%.

The top shareholders of Lincoln Pharma include the promoters, who are the majority shareholders. The promoter with the highest holding is Munjal Mahendrabhai Patel, owning 13.37% of the company. Additionally, individual investors hold a significant portion at 36.27%. In terms of institutional investment, 53 foreign institutional investors (FIIs) collectively hold 5.14%, while mutual funds have a minimal presence with holdings from 2 schemes at 0.0%. The highest public shareholder is Kishor M. Shah, who holds 2.39%.

How big is Lincoln Pharma.?

As of 24th July, Lincoln Pharmaceuticals Ltd has a market capitalization of 1,111.00 Cr, with recent net sales of 623.22 Cr and a net profit of 82.35 Cr. The balance sheet for March 2024 shows shareholder's funds of 592.84 Cr and total assets of 700.29 Cr.

As of 24th July, Lincoln Pharmaceuticals Ltd has a market capitalization of 1,111.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Lincoln Pharmaceuticals reported Net Sales of 623.22 Cr and a Net Profit of 82.35 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 592.84 Cr and Total Assets of 700.29 Cr.

Are Lincoln Pharma. latest results good or bad?

Lincoln Pharmaceuticals' latest results show a mixed performance, with a record Profit After Tax of Rs 27.68 crore and improved efficiency, but concerns arise from high reliance on non-operating income and declining growth rates. The stock is rated as a 'Sell' by MarketsMOJO, indicating cautious sentiment about its financial stability.

Lincoln Pharmaceuticals' latest results present a mixed picture. On one hand, the company achieved a Profit After Tax (PAT) of Rs 27.68 crore, which is the highest in the last five quarters, indicating a positive trend in profitability. The Earnings per Share (EPS) also reached Rs 13.82, reflecting enhanced earnings for shareholders.<BR><BR>Additionally, the Debtors Turnover Ratio improved to 3.75 times, showcasing better efficiency in managing debt collection. However, there are concerns regarding the sustainability of its business model, as a significant portion of its Profit Before Tax (PBT)—43.15%—came from Non-Operating Income, which raises questions about reliance on non-core activities.<BR><BR>In terms of growth, while the company reported a 4.61% increase in net sales year-over-year, this is a decline compared to the previous year's growth of 8.60%. Similarly, the consolidated net profit growth of 16.94% is lower than the 24.51% seen in the prior year.<BR><BR>Overall, while there are some positive indicators, the reliance on non-operating income and declining growth rates suggest caution. The stock has also been rated as a 'Sell' by MarketsMOJO, reflecting a cautious sentiment regarding its financial stability.

How has been the historical performance of Lincoln Pharma.?

Lincoln Pharma has shown consistent growth in net sales and profits, with net sales increasing from 366.15 Cr in March 2019 to 623.23 Cr in March 2025, and operating profit rising from 72.87 Cr to 123.97 Cr during the same period, despite some fluctuations in profit margins. Total assets and liabilities have also significantly increased, reflecting robust overall growth.

Answer:<BR>The historical performance of Lincoln Pharma shows a consistent growth trajectory in net sales and profit over the years.<BR><BR>Breakdown:<BR>Lincoln Pharma's net sales have increased from 366.15 Cr in March 2019 to 623.23 Cr in March 2025, reflecting a steady upward trend. Total operating income has followed a similar pattern, rising from 366.15 Cr to 623.23 Cr during the same period. The company's total expenditure, excluding depreciation, has also grown, from 298.91 Cr in March 2019 to 521.74 Cr in March 2025. Despite this increase in expenses, operating profit (PBDIT) has shown resilience, climbing from 72.87 Cr to 123.97 Cr, although it peaked at 134.33 Cr in March 2024. Profit before tax reached 109.19 Cr in March 2025, down from 122.24 Cr in March 2024, while profit after tax was 82.35 Cr in March 2025, a decrease from 93.30 Cr in the previous year. The company's total assets have significantly increased from 389.39 Cr in March 2020 to 797.01 Cr in March 2025, indicating robust growth in its asset base. Total liabilities also rose from 389.39 Cr to 797.01 Cr over the same period. Cash flow from operating activities improved to 93.00 Cr in March 2025, up from 63.00 Cr in March 2024, contributing to a net cash inflow of 7.00 Cr in March 2025. Overall, Lincoln Pharma has demonstrated a solid performance with increasing revenues and profits, despite some fluctuations in profit margins and expenses.

Is Lincoln Pharma. technically bullish or bearish?

As of November 20, 2025, Lincoln Pharma's technical outlook is bearish, driven by bearish daily moving averages and KST indicators, despite a mildly bullish signal from Dow Theory on the weekly chart.

As of 20 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include the daily moving averages, which are bearish, and the KST on both weekly and monthly time frames, which are also bearish. The monthly Bollinger Bands indicate a mildly bearish trend, while the Dow Theory shows a mildly bullish signal on the weekly but remains bearish on the monthly. Overall, the combination of these indicators suggests a bearish outlook for Lincoln Pharma.

Which are the latest news on Lincoln Pharma.?

Why is Lincoln Pharma. falling/rising?

As of 03-Dec, Lincoln Pharmaceuticals Ltd's stock price is declining at 499.95, down 0.09% and has fallen for three consecutive days, totaling a 2.38% drop. The company has underperformed the market with a -33.70% return over the past year, alongside declining profits and negative sentiment reflected in its stock trading below moving averages.

As of 03-Dec, Lincoln Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 499.95, which reflects a change of -0.45 (-0.09%). The stock has been on a downward trend, having fallen for the last three consecutive days, resulting in a total decline of -2.38% during this period. Additionally, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish sentiment.<BR><BR>Over the past year, Lincoln Pharma has significantly underperformed the market, generating a return of -33.70% compared to the BSE500's positive return of 2.66%. This poor performance is further highlighted by a decline in profits, with a reported fall of -17.2% in the company's earnings despite a low Debt to Equity ratio and an attractive valuation based on its Price to Book Value.<BR><BR>The company's recent financial results have also contributed to the negative sentiment. For instance, the profit after tax (PAT) for the quarter ending September 25 fell by -24.1%, and the return on capital employed (ROCE) reached its lowest at 15.46%. Furthermore, domestic mutual funds hold no stake in the company, which may indicate a lack of confidence in its future prospects.<BR><BR>Overall, the combination of poor long-term growth, declining profits, and underperformance relative to the market has led to a negative outlook for Lincoln Pharmaceuticals Ltd, resulting in its falling stock price.